Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Deutsche Bank Upgrades Penn National Gaming to Hold

Deutsche Bank analyst Carlo Santarelli upgrades Penn National Gaming (NASDAQ:PENN) from Sell to Hold.

byBenzinga Newsdesk

November 12, 2021

1 minute read

Deutsche Bank analyst Carlo Santarelli upgrades Penn National Gaming (NASDAQ:PENN) from Sell to Hold.

HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $8

By Benzinga Newsdesk

Today, 1:50 PM

HC Wainwright & Co. analyst Yi Chen maintains Alimera Sciences (NASDAQ:ALIM) with a Buy and lowers the price target from $10 to $8.

ALIM

News

U.S. Commerce Secretary Says Companies In Chip Supply Chain Like Taiwan Semiconductor, Samsung Have Pledged To Submit ‘Complete’ Data On Department’s Request On Semiconductor Crisis

By Benzinga Newsdesk

Today, 1:50 PM

-Reuters

SPY

Xencor Presents Data From Phase 1 Study Of Plamotamab In Relapsed Or Refractory Non-Hodgkin Lymphoma At The American Society Of Hematology Annual Meeting

By Benzinga Newsdesk

Today, 1:50 PM

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from

XNCR

Should You Buy Columbia Care Shares Right Now? This Analyst Explains

By Nina Zdinjak

Today, 1:50 PM

Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) recently reported its financial and operating resul

CCHWF

Deutsche Bank Upgrades Penn National Gaming to Hold

Related Posts

HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $8

U.S. Commerce Secretary Says Companies In Chip Supply Chain Like Taiwan Semiconductor, Samsung Have Pledged To Submit ‘Complete’ Data On Department’s Request On Semiconductor Crisis

Xencor Presents Data From Phase 1 Study Of Plamotamab In Relapsed Or Refractory Non-Hodgkin Lymphoma At The American Society Of Hematology Annual Meeting

Should You Buy Columbia Care Shares Right Now? This Analyst Explains